Ernexa Therapeutics Inc. (ERNA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
19/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinERNA / S&P 33.00% / 15.20% |
LoseERNA / S&P ERNA unavailable / 15.00% |
LoseERNA / S&P -88.08% / 50.40% |
| 2026-Q10/3 |
LoseERNA / S&P -83.33% / -4.33% |
LoseERNA / S&P ERNA unavailable / 11.30% |
LoseERNA / S&P -74.75% / 27.70% |
| 2025-Q42/3 |
WinERNA / S&P 9.09% / 2.65% |
LoseERNA / S&P ERNA unavailable / 9.00% |
WinERNA / S&P 130.05% / 13.40% |
| 2025-Q30/3 |
LoseERNA / S&P -40.22% / 8.12% |
LoseERNA / S&P ERNA unavailable / 4.61% |
LoseERNA / S&P -84.02% / 13.45% |
| 2025-Q21/3 |
LoseERNA / S&P -31.85% / 10.94% |
LoseERNA / S&P ERNA unavailable / 4.83% |
WinERNA / S&P 370.44% / 10.63% |
| 2025-Q11/3 |
LoseERNA / S&P -37.93% / -4.27% |
LoseERNA / S&P ERNA unavailable / 4.98% |
WinERNA / S&P 1977.88% / 10.57% |
| 2024-Q41/3 |
LoseERNA / S&P -72.38% / 2.41% |
LoseERNA / S&P ERNA unavailable / 5.25% |
WinERNA / S&P 678.92% / 6.15% |
| 2024-Q31/3 |
LoseERNA / S&P -42.62% / 5.89% |
LoseERNA / S&P ERNA unavailable / 5.89% |
WinERNA / S&P 2208.33% / 6.11% |
| 2024-Q21/3 |
LoseERNA / S&P -23.75% / 4.28% |
LoseERNA / S&P ERNA unavailable / 5.38% |
WinERNA / S&P 245.76% / 5.12% |
| 2024-Q11/3 |
WinERNA / S&P 33.33% / 10.56% |
LoseERNA / S&P ERNA unavailable / 5.71% |
LoseERNA / S&P -25.83% / 5.59% |
| 2023-Q40/3 |
LoseERNA / S&P -17.43% / 11.69% |
LoseERNA / S&P ERNA unavailable / 6.81% |
LoseERNA / S&P -50.06% / 7.78% |
| 2023-Q30/3 |
LoseERNA / S&P -3.54% / -3.27% |
LoseERNA / S&P ERNA unavailable / 7.52% |
LoseERNA / S&P -43.19% / -5.03% |
| 2023-Q20/3 |
LoseERNA / S&P -33.53% / 8.74% |
LoseERNA / S&P ERNA unavailable / 9.50% |
LoseERNA / S&P -85.93% / -8.57% |
| 2023-Q10/3 |
LoseERNA / S&P 5.59% / 7.50% |
LoseERNA / S&P ERNA unavailable / 10.77% |
LoseERNA / S&P -84.76% / -15.69% |
| 2022-Q40/3 |
LoseERNA / S&P -35.60% / 7.56% |
LoseERNA / S&P ERNA unavailable / 11.88% |
LoseERNA / S&P -76.50% / -17.99% |
| 2022-Q30/3 |
LoseERNA / S&P -51.92% / -4.88% |
LoseERNA / S&P ERNA unavailable / 13.47% |
LoseERNA / S&P -80.72% / -1.41% |
| 2022-Q21/3 |
LoseERNA / S&P -74.63% / -16.10% |
LoseERNA / S&P ERNA unavailable / 13.71% |
WinERNA / S&P 1619.20% / 11.04% |
| 2022-Q11/3 |
LoseERNA / S&P -50.84% / -4.60% |
LoseERNA / S&P ERNA unavailable / 15.97% |
WinERNA / S&P 1673.11% / 42.23% |
| 2021-Q41/3 |
LoseERNA / S&P -55.16% / 11.03% |
LoseERNA / S&P ERNA unavailable / 15.00% |
WinERNA / S&P 2201.99% / 96.40% |
| 2021-Q30/3 |
LoseERNA / S&P -48.36% / 0.58% |
LoseERNA / S&P ERNA unavailable / 10.77% |
LoseERNA / S&P ERNA unavailable / 69.42% |
| 2021-Q21/3 |
WinERNA / S&P 384.14% / 8.55% |
LoseERNA / S&P ERNA unavailable / 6.58% |
LoseERNA / S&P ERNA unavailable / 51.81% |
| 2021-Q10/3 |
LoseERNA / S&P -16.96% / 6.17% |
LoseERNA / S&P ERNA unavailable / -1.06% |
LoseERNA / S&P ERNA unavailable / 7.39% |
| 2020-Q41/3 |
WinERNA / S&P 31.76% / 12.15% |
LoseERNA / S&P -70.72% / -3.72% |
LoseERNA / S&P ERNA unavailable / -33.42% |
| 2020-Q30/3 |
LoseERNA / S&P -22.73% / 8.93% |
LoseERNA / S&P -52.36% / -2.04% |
LoseERNA / S&P ERNA unavailable / -27.10% |
| 2020-Q21/3 |
WinERNA / S&P 44.74% / 20.54% |
LoseERNA / S&P -41.33% / -0.46% |
LoseERNA / S&P ERNA unavailable / -27.11% |
| 2020-Q10/3 |
LoseERNA / S&P -30.91% / -19.60% |
LoseERNA / S&P -22.49% / 3.47% |
LoseERNA / S&P ERNA unavailable / -14.75% |
| 2019-Q40/3 |
LoseERNA / S&P -34.52% / 9.07% |
LoseERNA / S&P -15.12% / 5.36% |
LoseERNA / S&P ERNA unavailable / 2.99% |
| 2019-Q30/3 |
LoseERNA / S&P -11.35% / 1.70% |
LoseERNA / S&P -9.49% / 5.02% |
LoseERNA / S&P ERNA unavailable / 0.21% |
| 2019-Q20/3 |
LoseERNA / S&P -5.96% / 4.30% |
LoseERNA / S&P 0.34% / 6.64% |
LoseERNA / S&P ERNA unavailable / 8.65% |
| 2019-Q11/3 |
WinERNA / S&P 106.67% / 13.65% |
LoseERNA / S&P 2.76% / 8.12% |
LoseERNA / S&P ERNA unavailable / 14.29% |
| 2018-Q41/3 |
LoseERNA / S&P -56.18% / -13.52% |
WinERNA / S&P 9.69% / 9.05% |
LoseERNA / S&P ERNA unavailable / 18.23% |
| 2018-Q30/3 |
LoseERNA / S&P 0.23% / 7.71% |
LoseERNA / S&P 3.43% / 10.21% |
LoseERNA / S&P ERNA unavailable / 19.06% |
| 2018-Q20/3 |
LoseERNA / S&P -34.71% / 3.43% |
LoseERNA / S&P -1.34% / 9.03% |
LoseERNA / S&P ERNA unavailable / 14.46% |
| 2018-Q11/3 |
WinERNA / S&P 61.52% / -0.76% |
LoseERNA / S&P -1.16% / 7.68% |
LoseERNA / S&P ERNA unavailable / 12.46% |
| 2017-Q40/3 |
LoseERNA / S&P -31.21% / 6.64% |
LoseERNA / S&P -4.65% / 7.03% |
LoseERNA / S&P ERNA unavailable / 13.82% |
| 2017-Q30/3 |
LoseERNA / S&P -10.00% / 4.48% |
LoseERNA / S&P -3.92% / 5.68% |
LoseERNA / S&P ERNA unavailable / 17.57% |
| 2017-Q20/3 |
LoseERNA / S&P -20.93% / 3.09% |
LoseERNA / S&P -5.47% / 4.83% |
LoseERNA / S&P ERNA unavailable / 17.74% |
| 2017-Q10/3 |
LoseERNA / S&P 1.18% / 6.07% |
LoseERNA / S&P -9.12% / 3.67% |
LoseERNA / S&P ERNA unavailable / 13.32% |
| 2016-Q41/3 |
WinERNA / S&P 19.72% / 3.82% |
LoseERNA / S&P -9.00% / 2.09% |
LoseERNA / S&P ERNA unavailable / 7.05% |
| 2016-Q30/3 |
LoseERNA / S&P -17.44% / 3.85% |
LoseERNA / S&P -7.66% / 0.20% |
LoseERNA / S&P ERNA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ERNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -85.74% | 20.78% |
| Annualized return | -85.74% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ERNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.99% | 83.14% |
| Annualized return | -86.09% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ERNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -63.16% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |